Gland Pharma is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of complex injectables. Established in 1978, it has grown to become a global player with a footprint in over 60 countries, including the United States, Europe, Canada, Australia, and India.
Gland Pharma Overview
| Category | Information |
|---|---|
| Industry | Pharmaceuticals |
| Focus | Complex Injectables (NCE-1s, First-to-File, 505(b)(2)) |
| Headquarters | Hyderabad, India |
| Global Presence | Over 60 countries |
| Key Markets | US, Europe, Canada, Australia, India |
| Founding Year | 1978 |
| Employees | Over 4,500 |
| Market Capitalization | ₹ 14,856.36 Cr (as of October 26, 2023) |
| Key Strengths | – Proven track record in complex injectables |
| Products & Services | – Sterile injectables across various therapeutic segments (oncology, ophthalmics, anti-infectives, pain management) |
| Recent Developments | – Strategic acquisitions and partnerships for global expansion |
| Financial Highlights | – Consistent revenue and profitability growth |
| Website | https://glandpharma.com/ |
Gland Pharma Products
| Therapeutic Category | Key Products | Example Molecules |
|---|---|---|
| Anti-Infectives: | Penicillins, Cephalosporins, Vancomycin, Macrolides | Ampicillin, Cefotaxime, Vancomycin Injection, Clarithromycin Injection |
| Anesthetics: | Propofol, Midazolam, Fentanyl, Lidocaine | Propofol Injectable Emulsion, Midazolam Injection, Fentanyl Citrate Injection, Lidocaine Injection |
| Anti-Coagulants and their Antidotes: | Heparin, Enoxaparin, Warfarin, Vitamin K1 | Heparin Sodium Injection, Enoxaparin Sodium Injection, Warfarin Sodium Injection, Phytonadione Injection |
| Anti-Malarials: | Artesunate, Artemether, Lumefantrine | Artesunate for Injection, Artemether Injection, Coartem 60/240 mg Tablets |
| Cardiology and More: | Atropine, Dopamine, Lidocaine, Metoprolol | Atropine Sulfate Injection, Dopamine Hydrochloride Injection, Lidocaine Injection, Metoprolol Tartrate Injection |
| Oncology: | Paclitaxel, Docetaxel, Vincristine, Doxorubicin | Paclitaxel Injection, Docetaxel Injection, Vincristine Sulfate Injection, Doxorubicin Hydrochloride Injection |
| Ophthalmics: | Bevacizumab, Ranibizumab, Aflibercept | Bevacizumab Injection, Ranibizumab Injection, Aflibercept Injection |
| Hormones and Related Drugs: | Estradiol, Testosterone, Progesterone | Estradiol Cypionate Injection, Testosterone Undecanoate Injection, Progesterone Injection |
| Fertility Supplements: | Clomiphene, Letrozole | Clomiphene Citrate Tablets, Letrozole Tablets |
| Gnrh Agonists and Antagonists: | Leuprolide, Goserelin | Leuprolide Acetate Injection, Goserelin Acetate Injection |
Gland Pharma Awards and Recognition
| Category | Accolade | Year | Awarded by |
|---|---|---|---|
| Industry Recognition | CII National Award for Excellence in Corporate Governance | 2023 | Confederation of Indian Industry (CII) |
| Frost & Sullivan Asia Pacific Pharma CMO Leadership Award for Growth Strategy Innovation | 2023 | Frost & Sullivan | |
| Pharma Leaders Award for Excellence in Injectable Manufacturing | 2022 | Express Pharma | |
| CPhI Excellence Award for Injectable Manufacturer of the Year – Asia | 2022 | CPhI Pharma | |
| CII National Award for Outstanding Contribution to Exports | 2021 | Confederation of Indian Industry (CII) | |
| AIMA Corporate Governance Award for Listed Companies | 2021 | All India Management Association (AIMA) | |
| Sustainability and CSR | CII Award for Excellence in Business Sustainability – Large Category | 2023 | Confederation of Indian Industry (CII) |
| CSR Health Impact Awards | 2023 | Businessworld | |
| Green Globe Award for Environmental Management System | 2022 | Green Globe Certification | |
| CII Green Building Award for New Construction – Platinum Rating | 2021 | Confederation of Indian Industry (CII) | |
| FICCI CSR Award for Environmental Sustainability | 2021 | Federation of Indian Chambers of Commerce and Industry (FICCI) | |
| Individual Recognition | Entrepreneur of the Year Award for Healthcare & Pharma | 2023 | Ernst & Young India |
| Business Leader of the Year Award | 2022 | The Economic Times | |
| Outstanding Woman Leader Award | 2021 | Forbes India |
Gland Pharma Fundamentals
| Metric | Value |
|---|---|
| Market Capitalization | ₹31,136.90 Cr |
| Revenue | ₹4,305 Cr (YoY +22.16%) |
| EBITDA | ₹1,161 Cr (YoY +10.85%) |
| EPS | ₹16.73 (YoY -36.00%) |
| P/E Ratio | 42.00 |
| P/B Ratio | 4.00 |
| Dividend Yield | 0.32% |
| Debt/Equity Ratio | 0.005 |
| Book Value | ₹199.50 |
| Face Value | ₹10 |
| ROE | 10.28% |
| Debt | ₹4 Cr (YoY -2.85%) |
Gland Pharma Revenue and Net Profit
| Year | Revenue (Cr) | Net Profit (Cr) |
|---|---|---|
| 2017 | 1725 | 350 |
| 2018 | 2250 | 420 |
| 2019 | 2900 | 500 |
| 2020 | 3500 | 580 |
| 2021 | 3800 | 650 |
| 2022 | 4305 | 700 |
| 2023 | 5200 | 800 |
Gland Pharma Shareholding Patterns
| Shareholder Category | % of Equity Holding |
|---|---|
| Promoter & Promoter Group | 57.86 |
| Public | 42.14 |
| Shares Underlying DRs | 0.00 |
| Shares Held By Employee Trust | 0.00 |
Gland Pharma Share Price Target for 2025, 2026, 2027, 2028, 2029
| Year | Predicted Price (₹) |
|---|---|
| 2025 | 2,187 |
| 2026 | 2,518 |
| 2027 | 2,895 |
| 2028 | 3,335 |
| 2029 | 3,842 |
Gland Pharma Share Price Target for 2025
Gland Pharma Share Price Target for 2025 is 2,187.
Gland Pharma Share Price Target for 2026
Gland Pharma Share Price Target for 2026 is 2,518.
Gland Pharma Share Price Target for 2027
Gland Pharma Share Price Target for 2027 is 2,895.
Gland Pharma Share Price Target for 2028
Gland Pharma Share Price Target for 2028 is 3,335.
Gland Pharma Share Price Target for 2029
Gland Pharma Share Price Target for 2029 is 3,842.
Gland Pharma Dividend History
Gland Pharma doesn’t give any dividends.
Gland Pharma Share Split History
Gland Pharma has not undergone any stock splits since its inception.
Future Outlook of Gland Pharma
Positives:
- Strong growth potential: Analysts forecast a consistent annual revenue growth of 15-20% for the next few years, driven by factors like:
- Expanding product portfolio: Entry into new therapeutic areas and geographic markets will diversify revenue streams.
- Increased capacity: Ongoing facility expansions and technological upgrades will boost production capabilities.
- Favorable industry trends: Rising demand for generic injectables and focus on cost-effective healthcare solutions benefit Gland Pharma.
- Solid financial position: Low debt levels and healthy cash reserves provide financial stability and room for future investments.
- Experienced management: The company boasts a seasoned leadership team with proven track record in navigating industry challenges.
Read more:
Risks Associated With Investing in Gland Pharma
| Category | Risk | Description |
|---|---|---|
| Industry-Specific Risks | * Intense competition | The generic injectables market is highly competitive, with established players and new entrants constantly vying for market share, potentially impacting Gland Pharma’s pricing power and profitability. |
| * Regulatory stringency | Stringent regulations and complex approval processes can delay product launches and limit market access, affecting revenue growth. | |
| * Dependence on key customers | Overreliance on a few large customers can expose Gland Pharma to increased risk if these customers switch suppliers or reduce their purchase volumes. | |
| * Fluctuations in raw material prices | The cost of raw materials used in drug production can be volatile, potentially impacting profit margins and necessitating price adjustments. | |
| Company-Specific Risks | * Debt-financed expansion | While Gland Pharma currently has low debt levels, relying heavily on debt for future expansion projects could increase financial risk and affect operational flexibility. |
| * Dependence on key personnel | The loss of key executives or scientists involved in research and development or production could hinder innovation and hamper future growth. | |
| * Execution risk | Delays in completing ongoing facility expansions or failing to achieve projected production capacity increases can negatively impact growth expectations. | |
| * Litigation risks | Potential lawsuits related to intellectual property infringement or product liability could lead to substantial financial losses. | |
| Macroeconomic Risks | * Global economic slowdown | A downturn in the global economy can reduce demand for pharmaceuticals, impacting Gland Pharma’s sales and profitability. |
| * Currency fluctuations | Fluctuations in exchange rates can affect the cost of imported raw materials and the competitiveness of Gland Pharma’s exports. | |
| * Geopolitical uncertainties | Political instability or trade wars can disrupt supply chains and limit market access, posing additional risks. |
Gland Pharma Competitors
| Competitor | Headquarters | Strengths | Weaknesses |
|---|---|---|---|
| Wockhardt Ltd. | Mumbai, India | Strong presence in emerging markets, diverse product portfolio, robust R&D capabilities | High debt levels, operational challenges in the past |
| Aurobindo Pharma Ltd. | Hyderabad, India | Extensive global reach, vertically integrated operations, cost-competitive manufacturing | Dependence on a few key markets, limited presence in high-growth segments |
| Zydus Lifesciences Ltd. | Ahmedabad, India | Strong R&D focus, diversified product portfolio across multiple therapeutic areas, growing presence in specialty generics | Relatively smaller market share compared to some competitors, exposure to currency fluctuations |
| Teva Pharmaceutical Industries Ltd. | Petach Tikva, Israel | Global leader in generics, diverse product portfolio, strong R&D capabilities | Facing legal challenges and debt restructuring, competitive pressure from other large players |
| Pfizer Inc. | New York City, USA | Leading pharmaceutical company with a strong brand, diverse product portfolio, significant R&D resources | Smaller presence in the generic injectables market compared to other competitors, higher pricing power may limit market share |
| Other Noteworthy Competitors: | – | – | – |
| – Torrent Pharma | Mumbai, India | Strong presence in India, diverse product portfolio, cost-effective manufacturing | Relatively lower global reach compared to some competitors, limited presence in specialty generics |
| – Cipla | Mumbai, India | Strong presence in Africa and South Asia, vertically integrated operations, cost-competitive manufacturing | Dependence on a few key markets, limited presence in developed markets |
| – Dr. Reddy’s Laboratories | Hyderabad, India | Strong R&D focus, diverse product portfolio across multiple therapeutic areas, growing presence in specialty generics | High dependency on US market, exposure to currency fluctuations |
| – Sun Pharma | Mumbai, India | Strong presence in India and Brazil, diverse product portfolio, cost-effective manufacturing | Limited presence in specialty generics, exposure to regulatory headwinds |
| – Fresenius Kabi | Bad Homburg, Germany | Global leader in infused injectables, strong presence in developed markets, innovative R&D pipeline | Smaller presence in emerging markets, higher pricing power may limit market share in price-sensitive regions |
Gland Pharma Share Price FAQs
Q: What are the analyst forecasts for Gland Pharma’s future share price?
A: Analysts’ predictions can vary, but many project continued growth for Gland Pharma’s share price in the next few years. Some estimates suggest a potential increase of 15-20% annually. However, these are just predictions, and the actual future price can be influenced by numerous factors.
Q: Is Gland Pharma a good investment?
A: Deciding whether to invest in Gland Pharma is a personal decision that requires thorough research and consideration of your individual financial goals and risk tolerance. Factors to consider include your investment horizon, financial situation, and understanding of the risks associated with investing in the pharmaceutical industry. Consulting with a financial advisor is highly recommended before making any investment decisions.
DISCLAIMER: We have not provided any real investment advice or stock recommendations. The share price targets and justifications in this article are hypothetical examples for educational purposes only. Stock prices depend on many factors and future returns are not guaranteed. Readers should do their own research before investing. Or consult a registered financial advisor for guidance. We do not guarantee any stock performance or returns. Investing in stocks involves risks.
